Drugs / TFC-003
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT06177678 | Feb → Sep 2024 | ocular hypertension, open-angle glaucoma | Kukje Pharma | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07662759 | Dec 2025 → Mar 2027 expected | ocular hypertension, open-angle glaucoma | Kukje Pharma | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TFC-003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07662759 ↗ |
| Route | Topical | “1 drop of TFC-003 ophthalmic solution twice a day for 4 weeks.” NCT06177678 ↗ |